Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418610 · ClinicalTrials.gov registry record · Phase 4
Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea
A Phase 4 study, sponsored by Clinical Research Center of the Carolinas.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03418610: Completed Phase 4 study, sponsored by Clinical Research Center of the Carolinas.
NCT03418610 is a Phase 4 study that has completed, run by Clinical Research Center of the Carolinas. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03418610, a Phase 4 study, has completed, sponsored by Clinical Research Center of the Carolinas.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.
Primary Outcome
The change in inflammatory lesion counts at week 12 compared to baseline
Interventions
- DRUG Azelaic Acid foam 15%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2019-01-09 |
| Phase | Phase 4 |
What the finished NCT03418610 record still lists
NCT03418610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Azelaic Acid foam 15% is the first listed.
NCT03418610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03418610 about?
NCT03418610 is a clinical study titled "Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea". This research study is being performed to evaluate the photographic evidence of the efficacy and tolerability of Azelaic Acid Foam 15% in the treatment of papulopustular rosacea.
What is the current status of trial NCT03418610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2017-12-06. Estimated completion is 2019-01-09.
What interventions are being tested in trial NCT03418610?
The interventions under investigation include: Azelaic Acid foam 15% (DRUG).
Who is sponsoring clinical trial NCT03418610?
This trial is sponsored by Clinical Research Center of the Carolinas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03418610's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI